Florida's drug price transparency law takes effectPharmacists in Florida can now share cost information with patients, thanks to a new law that took effect July 1. FDA withdraws draft guidance on biosimilarsKey factors in the decision included comments noting that the number of reference product lots biosimilar developers would need to purchase under the draft guidance if it were finalized could impact cost and efficiency. American Regent launches preservative-free generic Makena The product will be available in 1 ml preservative-free single-dose vials in a dosage strength of 250 mg/ml. Lupin, Mylan partner on global Enbrel biosimilar The two companies will work together to commercialize Lupin’s biosimilar of Enbrel (etanercept), which it has already submitted for European Medicines Agency for approval. ANI launches generic Questran The launch is part of ANI’s ongoing efforts to re-commercialize discontinued generics that the company recently acquired. FDA approves Aurobindo’s generic Invanz injection The product will launch in July into a market with annual sales of $387 million for the 12 months ended April 2018, according to IQVIA data. AAM adds associate members, board member Joining the AAM board of directors is Siggi Olafson, CEO of Hikma, who will represent the company on the board. Amneal, Actavis settle generic Rytary litigation Under the settlement, Ameal will grant Actavis a license to sell its generic Rytary on July 31, 2025, or earlier under certain circumstances. West-Ward rebranded as Hikma Pharmaceuticals USA West-Ward Pharmaceuticals has a new name as part of rebranding efforts by its parent company, London-based Hikma Pharmaceuticals. Heritage Pharma launches generic Provigil The product enters a market whose annual sales totaled roughly $112 million for the 12 months ended May 2018, according to IQVIA data. First Previous 201 202 203 204 205 Next Last